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with mastocytosis and HVA should receive venom im-
munotherapy (VIT) or not. Some authors believe that 
anaphylactic reactions in patients with mastocytosis are 
generally of a pseudoallergic nature  [6] . In this case VIT 
would not be helpful. Individual reports suggest more 
side effects during VIT in patients with mastocytosis  [1] . 
On the other hand, there is evidence from other studies 
that VIT may be safe and effective in the vast majority of 
patients with mastocytosis  [2, 7] . 
 Here we present a fatal sting reaction in a female pa-
tient with systemic mastocytosis. Our patient had noticed 
red macules at the proximal upper legs and at the trunk 
during her second pregnancy when she was 29 years old. 
About 3 years later she presented to our outpatient clinic. 
She also had a history of asthma, which had resolved and 
did not require medical treatment. Otherwise she was 
healthy, and she had no history of previous anaphylaxis. 
 Skin examination revealed multiple dark red-brown-
ish macules of about 0.5 cm diameter which were erective 
upon rubbing (Darier’s sign). Histological examination 
showed mast cell infiltration in the upper dermis. Rou-
tine laboratory parameters were without pathological 
findings. Baseline serum tryptase concentration was in-
creased to 57   g/l (95th percentile 11.4   g/l). Bone mar-
row biopsy showed spindle-shaped mast cells with ex-
pression of CD117. Abdominal sonography, gastroscopy, 
and colonoscopy were without pathological findings.
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 Abstract
 We report on a 33-year-old female patient with indolent sys-
temic mastocytosis and urticaria pigmentosa who died of an 
anaphylactic reaction after a yellow jacket sting. As she had 
no history of previous anaphylactic sting reaction, there was 
no testing performed in order to detect hymenoptera ven-
om sensitization. But even if a sensitization had been diag-
nosed, no venom immunotherapy (VIT) would have been 
recommended. It is almost certain that VIT would have saved 
her life and it is most likely that VIT is indicated in some pa-
tients with mastocytosis with no history of anaphylactic 
sting reaction. However, no criteria have been established in 
order to allow a selection of mastocytosis patients eligible 
for such a ‘prophylactic’ VIT.  Copyright © 2008 S. Karger AG, Basel
 
 
 Patients with mastocytosis and hymenoptera venom 
allergy (HVA) represent a particular risk group for very 
severe anaphylactic sting reactions  [1–3] . Several fatal 
sting reactions have been reported in such patients  [4, 5] . 
Nevertheless, it is still controversial whether patients 
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 Our diagnosis was an indolent systemic mastocytosis 
with urticaria pigmentosa. There was no indication for 
specific treatment. We prescribed an emergency kit, com-
posed of antihistamine drops, corticosteroid fluid, and 
an epinephrine autoinjector, and instructed the patient to 
carry it with her all the time and to use it in case of ana-
phylactic symptoms. As she had no history of anaphylac-
tic sting reactions, no further diagnostics were done. 
 One year later, when she was 33, the patient was stung 
into the neck by a yellow jacket. At that time, she did not 
carry her emergency kit with her. Initially she complained 
about tachycardia. Within a few minutes she collapsed, 
lost consciousness and gasped for about 10 min. When 
the emergency physician arrived, her blood pressure was 
undetectable, and the patient was deeply comatose. She 
was immediately intubated, and cardiopulmonary resus-
citation was started. Emergency therapy was successful 
and after hemodynamic stabilization the patient was 
transferred to an intensive care unit. Subsequently, how-
ever, she did not regain consciousness. Four days later she 
died of hypoxic brain damage which could be confirmed 
at autopsy. 
 VIT is a highly effective measure to prevent anaphy-
laxis to hymenoptera stings. In our patient there was no 
history of a prior anaphylactic sting reaction. Therefore, 
we did not perform tests to detect venom sensitization. 
But even if we had done so and had detected venom sen-
sitization, we would not have recommended VIT to her. 
As anaphylaxis is frequent in patients with mastocytosis 
it is part of our clinical routine to provide these patients 
with an emergency kit. Our patient did not carry her 
emergency kit with her when she was stung. It cannot be 
determined whether its use would have altered the out-
come. However, it is almost certain that prophylactic VIT 
would have saved the life of this individual patient. It is 
highly likely that VIT is indicated in some patients with 
mastocytosis even if there has been no preceding anaphy-
lactic sting reaction. The rationale for such an individual 
indication can be found in the striking coincidence of 
mastocytosis and HVA. However, thus far, there are not 
yet any established criteria which would allow the identi-
fication of patients possibly eligible for such a ‘prophylac-
tic’ VIT.
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